Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Cowen Financial Products LLC
-
Form SCHEDULE 13G UroGen Pharma Ltd. Filed by: Cowen Financial Products LLC
-
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
-
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
-
Form SC 13G/A UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
-
TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
-
TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
-
Form SC 13G UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
-
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
-
UroGen Pharma (URGN) Commences Share and Warrant Offering
-
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
-
TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
-
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
-
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
-
UroGen Pharma (URGN) Named Best Idea for 2024 at TD Cowen
-
UroGen Pharma to Present at Upcoming Investor Conferences
-
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
-
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
-
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
-
UroGen Pharma Announces March 2021 Conference Schedule
-
UroGen Pharma Announces March 2020 Investor Conference Schedule
-
UroGen Pharma to Present at March 2019 Investor Conferences
-
UroGen to Present at March 2018 Investor Conferences
-
UroGen to Present at March 2018 Investor Conferences
-
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
-
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
-
UroGen Pharma (URGN) Prices 1.46M Shares at $41
-
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
-
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
-
UroGen Pharma (URGN) Announces Proposed Public Offering of Ordinary Shares
-
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
-
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
-
Cowen Starts UroGen Pharma (URGN) at Outperform
-
UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
-
UroGen Pharma (URGN) Prices 4.473M Share IPO at $13/Sh
-
UroGen Pharma Announces Pricing of Initial Public Offering

